Treatment of Clostridium difficile infection: recent trial results.


Journal Article

Clostridium difficile is a major cause of infection worldwide and is associated with increasing morbidity and mortality in vulnerable patient populations. Metronidazole and oral vancomycin are the currently recommended therapies for the treatment of C. difficile infection (CDI) but are associated with unacceptably high rates of disease recurrence. Novel therapies for the treatment of CDI and prevention of recurrent CDI are urgently needed. Important developments in the treatment of CDI are currently underway and include: novel antibacterial agents with narrower antimicrobial spectra of activity, manipulation of the gut microbiota and enhancement of the host antibody immune response.

Full Text

Duke Authors

Cited Authors

  • Lewis, SS; Anderson, DJ

Published Date

  • 2013

Published In

Volume / Issue

  • 3 / 9

Start / End Page

  • 875 - 886

PubMed ID

  • 25525499

Pubmed Central ID

  • 25525499

International Standard Serial Number (ISSN)

  • 2041-6792

Digital Object Identifier (DOI)

  • 10.4155/cli.13.72


  • eng

Conference Location

  • England